FDA Allows U.S. Sales of Iclusig to Resume Under Strict Safety Surveillance

Drug Industry Daily
The FDA will allow Ariad Pharmaceuticals to resume U.S. sales of its leukemia drug Iclusig, but the drugmaker must now implement a host of stringent safety measures designed to address the drug’s risk of blood clots.

To View This Article:


Subscribe To Drug Industry Daily